Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical Trial

Results support current practice guidelines, emphasizing the importance of individualized dosing based on patient response.

Authors

Natalie R. Budilovsky-Kelley
Genie L. Bailey (ORCID: https://orcid.org/0000-0002-5818-3001)
SHARON L. WALSH (ORCID: https://orcid.org/0000-0002-9722-5681)
Michael Frost (ORCID: https://orcid.org/0000-0001-5539-1369)
Peter Almgren (ORCID: https://orcid.org/0000-0002-0473-0241)
Fredrik Tiberg (ORCID: https://orcid.org/0000-0003-0080-4490)
Elin Banke Nordbeck
Michelle R. Lofwall (ORCID: https://orcid.org/0000-0002-5911-0752)
Edward V. Nunes (ORCID: https://orcid.org/0000-0002-2055-3425)
Susanna Meyner (ORCID: https://orcid.org/0009-0001-4044-5587)
Stefan Peterson (ORCID: https://orcid.org/0000-0001-6970-7977)